TABLE 6.
Proviral load after treatment with tenofovir or AZT beginning one week after infectiona
| Condition or treatment | Mouse | Proviral load (%)
|
|
|---|---|---|---|
| Lavage specimen | Spleen | ||
| Untreated | U11 | 7.4 | 1.7 |
| U12 | 0.1 | 0.0 | |
| U13 | 15.4 | 1.9 | |
| U14 | 3.8 | 0.7 | |
| Tenofovir | T11 | 0.0 | 0.0 |
| T12 | 0.2 | 0.0 | |
| T13 | 15.9 | 1.8 | |
| T14 | 14.5 | 2.6 | |
| Untreated | U21 | 0.6 | 0.1 |
| U22 | ND | 3.0 | |
| U23 | 12.6 | 1.0 | |
| U24 | 11.6 | 0.8 | |
| AZT | A21 | 0.0 | 0.0 |
| A22 | ND | 0.6 | |
| A23 | 2.5 | 0.0 | |
| A24 | 0.1 | 0.0 | |
After human PBMC transfer and MT-2 inoculation (103 cells/mouse for the tenofovir group, and 104 cells/mouse for the AZT group), mice were left for one week before starting treatment with tenofovir or AZT. The control groups were injected with PBS instead of the drugs. Mice were sacrificed 7 or 12 days after treatment with AZT or tenofovir, respectively. Splenocytes, as well as cells from the abdominal cavity, were recovered for analysis as described in Materials and Methods. ND, not determined.